Skip to content

New Developments in Lymphoma

A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian

  • Home
  • About the Lymphoma Program
  • Clinical Trials
  • Lymphoma Treatments
  • Lymphoma FAQ
  • Collaborating Labs
  • Glossary
  • Contact Us
New Developments in Lymphoma

Tag: germinal center B-cell like diffuse large B-cell lymphoma

Scientists Identify Four New Genetic Subtypes of Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, has been categorized based on the cancer cell of origin as either activated B-cell (ABC) DLBCL or germinal center B-cell (GCB) DLBCL. Each subtype is associated with a certain degree of tumor vulnerability and a corresponding response to therapy.

The more that clinicians know about how a patient’s disease develops, the better equipped they are to devise an informed and precise treatment plan. Yet, between 10-20 percent of DLBCL cases are unclassified, providing little guidance for strategic intervention.

To shed light on the unclassified disease subtype and further define the composition of the ABC and GCB subtypes, the Weill Cornell Medicine and NewYork-Presbyterian Hospital Lymphoma Program’s Dr. John P. Leonard took part in an international research initiative led by the National Cancer Institute at the National Institutes of Health, with findings recently published in the New England Journal of Medicine.

Whereas prior studies of genetic subtyping investigated individual mutations, this research was among the first to examine how mutations in multiple genes may relate to disease pathogenesis and therapeutic response.

Researchers used next-generation sequencing technology to analyze nearly 600 DLBCL patient biopsy samples, contributed in part through the Lymphoma Program’s efforts in collaboration with the Alliance for Clinical Trials in Oncology. Based on the co-occurrence of genetic alterations that they observed, the team discovered four new genetic subtypes of DLBCL – MCD, BN2, N1 and EZB – enhancing science’s understanding of the genetic framework of this aggressive cancer.

2013_9_16_Weill Cornell5107“These findings will take us one step closer to potentially employing targeted agents as part of treatment for specific DLBCL subtypes,” says Dr. Leonard. “If we can specifically identify these lymphoma types and incorporate new agents that target relevant pathways, we will advance rational clinical trials with the aim to improve outcomes for patients based on the biology of their disease.”

Share this:

  • Facebook
  • Twitter
  • Email
  • More
  • Print
  • Reddit
  • LinkedIn

Like this:

Like Loading...
Author jacquiehemoncPosted on April 30, 2018Categories Laboratory Research, Lymphoma News, Patient Education, Research Publications, UncategorizedTags ABC-DLBCL, activated B-cell like diffuse large B-cell lymphoma, Alliance for Clinical Trials in Oncology, diffuse large B-cell lymphoma, DLBCL, DLBCL Subtypes, Dr. John Leonard, GCB-DLCBL, Genetic Subtypes, germinal center B-cell like diffuse large B-cell lymphoma, National Cancer Institute, National Institutes of Health, New England Journal of Medicine, Next-generation sequencingLeave a comment on Scientists Identify Four New Genetic Subtypes of Diffuse Large B-Cell Lymphoma

Search

The Lymphoma Program

520 East 70th Street
Starr Pavilion, 3rd Floor
(between York Avenue and FDR Drive)
New York, NY 10021
Phone: (646) 962-2064
Fax: (646) 962-1605
weillcornell.org/lymphoma

Social

Support Us

Enter your email address to follow this blog and receive notifications of new posts by email.

Recent Posts

  • Novel Three-Drug Combination of Ibrutinib plus Lenalidomide and Rituximab Shows Promising Anti-Lymphoma Activity in Relapsed/Refractory DLBCL
  • Mantle Cell Lymphoma PALIBR Outcomes Published Online in Blood Journal
  • Our Team’s Take on the Most Influential ASH 2018 Lymphoma Research
  • The Body’s Military Defense
  • 2018 American Society of Hematology (ASH) Annual Meeting
  • Home
  • About the Lymphoma Program
  • Clinical Trials
  • Lymphoma Treatments
  • Lymphoma FAQ
  • Collaborating Labs
  • Glossary
  • Contact Us
New Developments in Lymphoma Blog at WordPress.com.
Cancel
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: